DRZID
TEVA icon

DePrince Race & Zollo Inc (DRZ)’s Teva Pharmaceuticals TEVA Stock Holding History

DePrince Race & Zollo Inc (DRZ)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-662,902
Closed -$22M – 266
2017
Q2 		$22M Buy
662,902
+4,307
+0.7% +$133K 0.45% 108
2017
Q1 		$21.1M Sell
658,595
-136,779
-17% -$4.67M 0.44% 115
2016
Q4 		$28.8M Buy
795,374
+202,650
+34% +$8.09M 0.56% 89
2016
Q3 		$27.3M Buy
592,724
+26,640
+5% +$1.39M 0.58% 88
2016
Q2 		$28.4M Buy
566,084
+486,894
+615% +$25.9M 0.58% 93
2016
Q1 		$4.24M Buy
+79,190
New +$4.65M 0.09% 160
2015
Q1 		– Sell
-18,630
Closed -$1.07M – 299
2014
Q4 		$1.07M Sell
18,630
-5,700
-23% -$318K 0.01% 258
2014
Q3 		$1.31M Sell
24,330
-837,201
-97% -$44.4M 0.02% 257
2014
Q2 		$45.2M Sell
861,531
-47,200
-5% -$2.41M 0.53% 81
2014
Q1 		$48M Sell
908,731
-189,920
-17% -$8.78M 0.58% 69
2013
Q4 		$44M Sell
1,098,651
-125,300
-10% -$4.93M 0.56% 70
2013
Q3 		$46.2M Buy
1,223,951
+47,633
+4% +$1.86M 0.63% 57
2013
Q2 		$46.1M Buy
+1,176,318
New +$45.8M 0.63% 56

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

DePrince Race & Zollo Inc (DRZ)'s TEVA Position: Q3 2017 in Review

DePrince Race & Zollo Inc (DRZ) sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 662,902 shares — an estimated $22M sold.

DePrince Race & Zollo Inc (DRZ) first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $48M in Q1 2014. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • DePrince Race & Zollo Inc (DRZ) reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • DePrince Race & Zollo Inc (DRZ) sold 662,902 Teva Pharmaceuticals shares in Q3 2017, an estimated $22M.
  • DePrince Race & Zollo Inc (DRZ) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • DePrince Race & Zollo Inc (DRZ)'s Teva Pharmaceuticals position peaked at $48M in Q1 2014.
  • 536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on DePrince Race & Zollo Inc (DRZ)'s 13F filing for Q3 2017, filed 7 Nov 2017.